Navigation Links
GENova appoints Dr. Wang Chong to Scientific Advisory Board

NEW YORK, NY, Sept. 14 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Wang Chong to its Scientific Advisory Board.

Dr. Wang Chong will contribute his considerable expertise to the company as it pursues its mandate to develop, patent and commercialize ground-breaking cancer-fighting biotechnologies, with a focus on breast and prostate cancer.

Aaron Whiteman, CEO of GENova stated, "GENova is proud to have attracted such an esteemed me member of the healthcare industry to assist us in our growth plans."

About Dr. Wang Chong

Dr. Wang Chong is a physician with over 19 years of experience in the healthcare industry, whose expertise lies in raising capital for and listing small to medium-sized companies. Previous positions include CFO and Commercial Director of Phytopharm plc, CEO of Osmetech plc, Life Sciences Analyst at Canaccord Capital (Europe) Ltd, Leader of UK Healthcare Initiatives at premier management consultants Arthur D. Little Inc, and commercial roles at Glaxo Wellcome plc and SmithKline Beecham plc. Chong graduated with a medical degree from King's College London and a MBA from London Business School. He is also a Council Member of the Royal Society of Medicine's Pharmaceutical Medicine Research Section and an Associate of the Securities and Investment Institute.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova appoints Dr. Philip Gould to Scientific Advisory Board
2. GENova issues clarifying press release
3. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
4. GENova files patent for new breast cancer treatment
5. GENova appoints Director of Asian business development
6. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
7. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
8. Genova files patent for new prostate cancer treatment
9. GENova names Dr. John Savin as Vice President
10. GENova names Aaron Whiteman as CEO
11. InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: